Article

Dual reporter comparative indexing of rAAV pseudotyped vectors in chimpanzee airway.

Department of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA.
Molecular Therapy (Impact Factor: 6.43). 10/2009; 18(3):594-600. DOI: 10.1038/mt.2009.230
Source: PubMed

ABSTRACT Selecting the most efficient recombinant adeno-associated virus (rAAV) serotype for airway gene therapy has been difficult due to cross-specific differences in tropism and immune response between humans and animal models. Chimpanzees--the closest surviving genetic relative of humans--provide a valuable opportunity to select the most effective serotypes for clinical trials in humans. However, designing informative experiments using this protected species is challenging due to limited availability and experimental regulations. We have developed a method using Renilla luciferase (RL) and firefly luciferase (FL) reporters to directly index the relative transduction and immune response of two promising rAAV serotypes following lung coinfection. Analysis of differential luciferase activity in chimpanzee airway brushings demonstrated a 20-fold higher efficiency for rAAV1 over rAAV5 at 90 days, a finding that was similar in polarized human airway epithelia. T-cell responses to AAV5 capsid were stronger than AAV1 capsid. This dual vector indexing approach may be useful in selecting lead vector serotypes for clinical gene therapy and suggests rAAV1 is preferred for cystic fibrosis.

Full-text

Available from: Christian Mueller, Jun 07, 2015
1 Follower
 · 
109 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The cystic fibrosis transmembrane conductance regulator (CFTR) gene was identified in 1989. This opened the door for development of CF gene therapy which has been actively pursued for the last 20 years. Although 26 clinical trials involving approximately 450 patients have been carried out, the vast majority of these trials were short and included small numbers of patients and not designed to assess clinical benefit, but to establish safety and proof-of-concept for gene transfer using molecular endpoints such as the detection of recombinant mRNA or correction of the ion transport defect. The only currently published trial designed and powered to assess clinical efficacy (defined as improvement in lung function) administered AAV2-CFTR to the lungs of CF patients. The UK CF Gene Therapy Consortium has recently (Autumn 2014) completed the first non-viral gene therapy trial designed to answer whether repeated non-viral gene transfer (12 doses over 12 months) can lead to clinical benefit. The demonstration that the molecular defect in CFTR can be corrected using small molecule drugs and the success of gene therapy in other monogenic diseases, is boosting interest in CF gene therapy. Recent developments are discussed here.
    Human gene therapy 04/2015; DOI:10.1089/hum.2015.027 · 3.62 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Large animal models of genetic diseases are rapidly becoming integral to biomedical research as technologies to manipulate the mammalian genome improve. The creation of cystic fibrosis (CF) ferrets and pigs is an example of such progress in animal modeling, with the disease phenotypes in the ferret and pig models more reflective of human CF disease than mouse models. The ferret and pig CF models also provide unique opportunities to develop and assess the effectiveness of gene and cell therapies to treat affected organs. In this review, we will examine the organ disease phenotypes in these new CF models and the opportunities to test gene therapies at various stages of disease progression in affected organs. We will then discuss the progress in developing recombinant replication-defective adenovirus, adeno-associated virus, and lentiviral vectors to target genes to the lung and pancreas in ferrets and pigs, the two most affected organs in CF. Through this review, we hope to convey the potential of these new animal models for developing CF gene and cell therapies.
    12/2014; 26(1). DOI:10.1089/hum.2014.154
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cystic Fibrosis (CF) is an autosomal disease associated with malfunction in fluid and electrolyte transport across several mucosal membranes. The most common mutation in CF is an in-frame three-base pair deletion that removes a phenylalanine at position 508 in the first nucleotide-binding domain of the cystic fibrosis conductance regulator (CFTR) chloride channel. This mutation has been studied extensively and leads to biosynthetic arrest of the protein in the endoplasmic reticulum and severely reduced channel activity. This review discusses a novel method of rescuing ΔF508 with transcomplementation, which occurs when smaller fragments of CFTR containing the wild-type nucleotide binding domain are co-expressed with the ΔF508 deletion mutant. Transcomplementation rescues the processing and channel activity of ΔF508 and reduces its rate of degradation in airway epithelial cells. To apply transcomplementation as a therapy would require that the cDNA encoding the truncated CFTR be delivered to cells. We also discuss a gene therapeutic approach based on delivery of a truncated form of CFTR to airway cells using adeno-associated viral vectors.
    Biophysical Reviews 03/2014; 6(1):169-180. DOI:10.1007/s12551-014-0137-3